title: Proteomic footprinting of drug-treated cancer cells as a measure of cellular vaccine efficacy for the prevention of cancer recurrence.
abstract: The comparative proteomic study of cell surfaces of native and drug-treated cancer cells was performed. To this end, cell proteomic footprinting, which reflects the mass spectrometry profiling of cell surface proteins, was applied to breast adenocarcinoma cells (MCF-7), which were untreated or treated with doxorubicin, tamoxifen, or etoposide. The footprints of drug-treated cells were compared with the footprints of untreated cells and the footprint of a randomly selected control cancer cell culture. It was found that drug-treated cells have reproducible, pronounced, and drug-specific changes in cell surface protein expression. Cytotoxicity assays, which are an in vitro model of human antitumor vaccination, revealed that the degree of these changes correlates directly with the ability of the cancer cells to escape cell death induced by a cytotoxic T-cell-mediated immune response. Moreover, cancer cells escape from the immune response was linearly approximated (R(2) equal to 0.99) with the degree by which their proteomic footprints diverged from the footprint of the targeted (native) cancer cells. From these findings, it was concluded that the design of anticancer vaccines intended to prevent cancer recurrence after primary treatment should consider the drug-specific changes in cancer cell-surface antigens. Such changes can be easily identified by cell proteomic footprinting, renewing hopes for development of efficient cellular cancer vaccines.
authors.affiliation: Cardiology Research Center, 3rd Cherepkovskaya St. 15A, 121552, Moscow, Russia.
authors.forename: Elena E
authors.initials: EE
authors.lastname: Balashova
authors.forename: Maxim I
authors.initials: MI
authors.lastname: Dashtiev
authors.forename: Petr G
authors.initials: PG
authors.lastname: Lokhov
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy / Q000276:immunology / Q000378:metabolism; D000903:Antibiotics, Antineoplastic / Q000494:pharmacology; D018931:Antineoplastic Agents, Hormonal / Q000494:pharmacology; D000972:Antineoplastic Agents, Phytogenic / Q000494:pharmacology; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000276:immunology / Q000378:metabolism*; D019496:Cancer Vaccines / Q000276:immunology*; D002853:Chromatography, Liquid; D003713:Dendritic Cells / Q000276:immunology / Q000378:metabolism; D004317:Doxorubicin / Q000494:pharmacology; D005047:Etoposide / Q000494:pharmacology; D005260:Female; D056945:Hep G2 Cells / Q000187:drug effects / Q000378:metabolism; D006801:Humans; D009364:Neoplasm Recurrence, Local / Q000175:diagnosis / Q000378:metabolism / Q000517:prevention & control*; D040901:Proteomics; D011956:Receptors, Cell Surface / Q000276:immunology / Q000378:metabolism*; D019032:Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology; D013629:Tamoxifen / Q000494:pharmacology; D014407:Tumor Cells, Cultured
chemical_list: D000903:Antibiotics, Antineoplastic; D018931:Antineoplastic Agents, Hormonal; D000972:Antineoplastic Agents, Phytogenic; D019496:Cancer Vaccines; D011956:Receptors, Cell Surface; D013629:Tamoxifen; D005047:Etoposide; D004317:Doxorubicin
references.citation: Neoplasia. 2000 Sep-Oct;2(5):449-59
references.pmid: 11191112
references.citation: Annu Rev Immunol. 1984;2:103-26
references.pmid: 6085749
references.citation: J Exp Med. 1994 Jul 1;180(1):83-93
references.pmid: 8006603
references.citation: Cancer Res. 1996 May 15;56(10):2237-44
references.pmid: 8625291
references.citation: Nat Rev Drug Discov. 2008 Dec;7(12):966-7
references.pmid: 19043443
references.citation: Adv Cancer Res. 2007;96:175-90
references.pmid: 17161680
references.citation: Rapid Commun Mass Spectrom. 2009 Mar;23(5):680-2
references.pmid: 19184978
references.citation: Int Rev Immunol. 2006 Sep-Dec;25(5-6):297-319
references.pmid: 17169778
references.citation: Lancet. 2002 Oct 12;360(9340):1131-5
references.pmid: 12387961
references.citation: Annu Rev Med. 2002;53:615-27
references.pmid: 11818492
references.citation: Adv Exp Med Biol. 2001;491:369-402
references.pmid: 14533809
references.citation: Biol Pharm Bull. 1996 Nov;19(11):1518-20
references.pmid: 8951178
references.citation: Nat Rev Cancer. 2006 Mar;6(3):204-16
references.pmid: 16498443
references.citation: J Immunol Methods. 2005 Apr;299(1-2):37-46
references.pmid: 15890354
references.citation: J Cancer. 2010 Nov 29;1:230-41
references.pmid: 21151581
references.citation: Expert Opin Ther Pat. 2009 May;19(5):623-41
references.pmid: 19441938